Exchange: NYSE·Updated 10:06 AM EST

CRL News

News
all
press releases
Charles River Laboratories International Q3 26 Earnings Conference Call At 9:00 AM ET
(RTTNews) - Charles River Laboratories International Inc. (CRL) will host a conference call at 9:00 AM ET on November 4th, 2026, to discuss Q3 26 earnings results...
Nasdaq News: Markets
Charles River Laboratories International Q3 26 Earnings Conference Call At 9:00 AM ET
(RTTNews) - Charles River Laboratories International Inc. (CRL) will host a conference call at 9:00 AM ET on November 4th, 2026, to discuss Q3 26 earnings results...
Nasdaq News: Markets
More News
Charles River Laboratories Lifts Annual Outlook- Update
(RTTNews) - Charles River Laboratories International, Inc. (CRL), a provider of drug discovery and development services, Wednesday raised its 2026 outlook for organic revenue growth and earnings per share...
Nasdaq News: Markets
Charles River Laboratories Announces Third-Quarter 2026 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter ended September 26, 2026. Key Highlights Reports third-quarter revenue of $982.7 million, GAAP earnings per share of $6.86, and non-GAAP earnings per share of $3.09. Organic revenue growth of...
Business Wire
Revvity (RVTY) Tops Q3 Earnings and Revenue Estimates
Revvity (RVTY) delivered earnings and revenue surprises of +6.98% and +0.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Charles River's Q3 Earnings on Deck: What's in Store for the Stock?
CRL's Q3'26 results face pressure from declining segment revenues, but improving biopharma demand and strength in Microbial Solutions could provide support.
Zacks
Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Charles River Leverages Virtual Control Groups in GLP Studies
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its Virtual Control Group (VCG) database and methodology, aimed at reducing animal use, will be used in an upcoming Good Laboratory Practice (GLP)-compliant study for Ipsen. This collaboration highlights Charles Rivers...
Business Wire
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) and Labcorp for developing sensitive screening tools to quantify and rank the abuse potential of new drugs, including abuse-deterrent...
Business Wire
$1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 4.33% on an annualized basis producing an average annual return of 17.1%. Currently, Charles River has a market capitalization of $15.34read more...
Benzinga

Advertisement|Remove ads.